View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
July 11, 2018

Diverse pipeline for Type 2 diabetes therapeutics

Type 2 diabetes (T2DM) is a chronic and progressive metabolic disorder associated with many different complications.

By GBI Research

Type 2 diabetes (T2DM) is a chronic and progressive metabolic disorder associated with many different complications.

Patients require increasingly complex treatment regimens with many different drug types.

The demand for T2DM therapeutics has resulted in a large and competitive market landscape, with a number of drugs competing with one another for different market segments, across multiple lines of therapy.

Since the mid-2000s, a number of new drug classes have entered the market, including glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 inhibitors, and sodium–glucose linked transporter-2 inhibitors.

These drug classes have proved to be highly commercially successful.

This has led to a diverse pipeline, with many new molecular target groups that do not exist or are poorly represented in the market.

The strong showing of G protein-coupled receptors (GPCRs) in the pipeline is a result of the success of GLP-1 receptor agonists.

The diversity of the pipeline suggests that a new wave of therapy types may become available to T2DM patients and aid in developing new and more effective treatment regimens.

Related reports

For more insight and data, visit the GBI Research report store.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU